HOME >> MEDICINE >> NEWS
Acrux patent portfolio advances in USA

  • New patent granted in USA for MDTS drug delivery system
  • Protection against copies of Acrux unique transdermal sprays extended out to 2022
  • Nine patents now granted in USA

Acrux has received notification of the grant of a US patent (number 6,978,945), which provides robust protection for its Metered Dose Transdermal Spray (MDTS)applicator for delivery of drugs. The applicator is currently used in the three women's health products that Acrux has under clinical development the contraceptive spray Nestorone MDTS, Testosterone MDTS to treat decreased libido and EvamistTM to treat menopause symptoms. EvamistTM is nearing completion of Phase 3 trials in the USA, with results expected to be available in the second quarter of 2006. The new patent does not expire until 31 July 2022, which is five years later than Acrux's other granted US patents.

Acrux CEO Igor Gonda commented "This new patent provides very broad protection for the familiar part of our products that the patient sees and uses. It means that copies of our unique transdermal spray devices that provide a precise and convenient means of drug delivery are now kept out of the market until 2022 at the earliest".

In addition, Acrux has been granted another US patent (number 6,998,138), expiring in 2017, which provides an additional layer of patent protection for delivery of anti-alopecia (baldness) drugs using Acrux's fast drying skin delivery technology. Alopecia treatments are a part of Acrux's valuable portfolio of dermatology products.


'"/>

Contact: Igor Gonda
61-383-790-100
Research Australia
1-Mar-2006


Page: 1

Related medicine news :

1. Acrux completes enrollment in key phase 2 trial
2. Acrux and Oreganon further expand their collaboration
3. Acrux granted first grant in Europe, triggering payment from Lilly
4. Acrux acquires rights to commercialise worlds first contraceptive spray
5. Four new us patents granted to Acrux for transdermal drug delivery
6. Acrux reports progress in development of Testosterone MD-Lotion(R) for men
7. Panbio files first patent application for Homogenous Assay Technology
8. GroPep awarded key patent for infertility treatment in Europe
9. Resonance Health Goup patent for diagnosis of liver fibrosis
10. VCR - US patent litigation update
11. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Acrux patent portfolio advances USA

(Date:5/21/2013)... Benefit Express Services, LLC, a leader in ... will be hosting a free Workplace Wellness webinar on ... The presentation will focus on making sure your workplace ... Health Care Reform Requirements. The team will also share ... Express regularly hosts free educational webinars on issues that ...
(Date:5/21/2013)... Three major Ohio universities and four hospitals have ... a new collaborative research program aimed exclusively at finding ... Dimes intends to invest $10 million in the program ... Prematurity Research Center -- Ohio Collaborative is a unique ... the March of Dimes. "This new transdisciplinary, team-based research ...
(Date:5/21/2013)... 2013 EMBO announced today that 52 outstanding researchers ... membership. Forty-three of the researchers reside in Europe and ... nine Associate Members from Canada, China, India, Japan and ... 1600 life scientists. , "Our members are the basis ... Maria Leptin said. "We have been building our network ...
(Date:5/21/2013)... Healthcare Solutions, the parent company ... announced that it was honored to receive the ... Conferred annually, the Innovation Award recognizes a ... cutting edge programs that improves cost and/or quality ... for its clinical and IT solutions that have ...
(Date:5/21/2013)... Two-thirds of patients who have been diagnosed ... that they engage in at least one type of ... findings from the National Health and Wellness Survey ... research will be presented today at the 18th Annual ... Outcomes Research) in New Orleans. , “Cancer ...
Breaking Medicine News(10 mins):Health News:Benefit Express to Host Workplace Wellness Webinar 2Health News:New multi-million dollar research center aims to solve the mystery of premature birth 2Health News:New multi-million dollar research center aims to solve the mystery of premature birth 3Health News:EMBO announces 52 new members for 2013 2Health News:Healthcare Solutions Receives Innovation Award From Catamaran 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 2Health News:Two in Three Cancer Patients are Non-Adherent with Their Medications, According to Kantar Health Research 3
(Date:5/21/2013)... May 21, 2013  BioRestorative Therapies, Inc. ("BRT" or ... focused on developing stem cell based therapies for various ... , its President and CEO, will be presenting at ... will be held on Thursday, May 30, 2013 at ... Street in New York City.  Mr. Weinreb,s presentation will ...
(Date:5/21/2013)... May 21, 2013  AcelRx Pharmaceuticals, Inc. ... pharmaceutical company focused on the development and ... of acute and breakthrough pain, today announced ... Phase 3 study of its investigational sublingual ... System), the primary efficacy endpoint was achieved.  ...
(Date:5/21/2013)...   RxAlly , a first-of-its-kind alliance of ... publication of a white paper entitled Personalized Pharmacist ... white paper highlights an unprecedented solution for improving ... to avert strains on the health care system. ... range of individually-tailored, pharmacist-provided clinical and consultative services ...
Breaking Medicine Technology:BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 2BioRestorative Therapies, Inc. to Present at the Marcum MicroCap Conference 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 2Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 3Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 4Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 5Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 6Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 7Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 8Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 9Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain 10RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 2RxAlly Releases White Paper on Necessity of Personalized Pharmacist Care 3
Cached News: